Posted August 9, 2010
Gisselbrecht C. J Clin Oncol. 2010;doi:10.1200/JCO.2010.28.1618.

Rituximab did not improve OS, PFS or event-free survival in patients who relapsed 1 year after a diffuse large B-cell lymphoma diagnosis, according to results from the Collaborative Trial in Relapsed Aggressive Lymphoma study.

For the phase 3, multinational study, researchers in 12 countries randomly assigned 202 patients to rituximab, ifosfamide, etoposide and carboplatin (R-ICE)...

admin

SOURCE: Sunesis Pharmaceuticals, Inc.

Jul 15, 2010 08:00 ET

SOUTH SAN FRANCISCO, CA--(Marketwire - July 15, 2010) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company's lead drug candidate, voreloxin, with cytarabine. Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), and the therapy used in combination with voreloxin in a fully...

admin

Celator® Pharmaceuticals Announces Data on Remissions With CPX-351 Following Induction Failure

-Results Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

PRINCETON, N.J., June 7

PRINCETON, N.J., June 7 /PRNewswire/ -- Celator Pharmaceuticals today announced that a subset analysis of data from its Phase 2 study in newly diagnosed acute myeloid leukemia (AML) demonstrates that CPX-351 (Cytarabine : Daunorubicin) Liposome Injection...

admin

Published May 17, 2010

Received for publication May 26, 2009, and accepted in revised form February 3, 2010.

Acute myeloid leukemia (AML) affects 10 in 100,000 individuals in the United States and is fatal without treatment. Standard chemotherapy consists of a combination of anthracycline and cytarabine and yields a 5-year survival rate of 20%–30% (1). Despite decades of clinical research, the treatment for AML has remained essentially unchanged for 30 years (1). Defects...

admin

By Crystal Phend, Senior Staff Writer, MedPage Today
Published: April 06, 2010
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

A DNA methyltransferase inhibitor that's effective against myelodysplastic syndrome also shows early promise in higher-risk older patients with acute myeloid leukemia (AML), researchers found.

Decitabine (Dacogen)...

admin